CAR-T immunotherapy

CAR-T immunotherapy

0 0 about 1 year ago
0 Plays 0 Downloads
Genetically engineered T cells constitute a powerful new class of therapeutic agents that provide hope for cancer relief in cancer patients. Last year, CAR-T immunotherapy was approved by the US FDA and entered the clinical practice of leukemia and lymphoma. Synthetic biology provides a broadly extended set of tools for cell engineering to reprogram immune cells to enhance their function. Advances in T cell engineering, gene editing, selection of the most potent lymphocytes, cell manufacturing, ... See More

Find us on Facebook

iAB member
Copyright 2019 - Spreaker Inc. a Voxnest Company - Create a podcast - New York, NY
Help